Literature DB >> 25684784

MORTALITY AFTER CLINICAL MANAGEMENT OF AIDS-ASSOCIATED CRYPTOCOCCAL MENINGITIS IN KENYA.

R Baldassarre, R Mdodo, E Omonge, W Jaoko, J Baddley, P Pappas, I Aban, S Odera, A Suleh, P E Jolly.   

Abstract

BACKGROUND: Cryptococcal meningitis (CM) is an increasingly prevalent infection among HIV/AIDS patients and is becoming a leading cause of morbidity and mortality in Africa. The short-term prognosis and management of patients with CM may be improved by identifying factors leading to mortality in patients with CM.
OBJECTIVE: To assess the clinical management and mortality associated with cryptococcal meningitis (CM) in patients with acquired immunodeficiency syndrome (AIDS) in Kenya.
DESIGN: A retrospective study.
SETTING: Kenyatta National Hospital and Mbagathi District Hospital, between August 2008 and March 2009.
SUBJECTS: Seventy six HIV-infected patients confirmed to be CM positive.
RESULTS: Results show that 30 (40%) of 76 patients diagnosed with CM died during hospitalisation after a median hospital stay of ten days (range, 2-73 days). Significant predictors of mortality in the univariate model were Mycobacterium tuberculosis (TB) co-infection (P = 0.04), having been diagnosed with a co-morbid condition such as diabetes mellitus, oral candidiasis and hypertension (P = 0.01), and a low median CD4+ T lymphocyte count (P < 0.001). The multivariable model revealed that male sex, previous or current anti-retroviral therapy (ART) at admission and CD4+ T lymphocyte count less than 50 were significant predictors of mortality. Conversely, a minimum of two weeks of amphotericin B treatment (P < 0.001), initiation of ART (P = 0.007) and monitoring of creatinine and electrolyte levels (P = 0.02) were significantly associated with survival in the univariate model.
CONCLUSIONS: CM-associated mortality in Kenya is high; there is an opportunity to improve the management and the short-term outcomes of hospitalised HIV positive patients with CM in Kenya.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25684784      PMCID: PMC4324694     

Source DB:  PubMed          Journal:  East Afr Med J        ISSN: 0012-835X


  15 in total

1.  Impact of HIV infection on meningitis in Harare, Zimbabwe: a prospective study of 406 predominantly adult patients.

Authors:  J G Hakim; I T Gangaidzo; R S Heyderman; J Mielke; E Mushangi; A Taziwa; V J Robertson; P Musvaire; P R Mason
Journal:  AIDS       Date:  2000-07-07       Impact factor: 4.177

Review 2.  HIV-associated cryptococcal meningitis.

Authors:  Joseph N Jarvis; Thomas S Harrison
Journal:  AIDS       Date:  2007-10-18       Impact factor: 4.177

3.  Cost-effectiveness of serum cryptococcal antigen screening to prevent deaths among HIV-infected persons with a CD4+ cell count < or = 100 cells/microL who start HIV therapy in resource-limited settings.

Authors:  David B Meya; Yukari C Manabe; Barbara Castelnuovo; Bethany A Cook; Ali M Elbireer; Andrew Kambugu; Moses R Kamya; Paul R Bohjanen; David R Boulware
Journal:  Clin Infect Dis       Date:  2010-08-15       Impact factor: 9.079

4.  Antifungal drug susceptibility of Cryptococcus neoformans from clinical sources in Nairobi, Kenya.

Authors:  Christine C Bii; Koichi Makimura; Shigeru Abe; Haruhiko Taguchi; Olga M Mugasia; Gutura Revathi; Njeri C Wamae; Shigeru Kamiya
Journal:  Mycoses       Date:  2007-01       Impact factor: 4.377

Review 5.  Estimation of the current global burden of cryptococcal meningitis among persons living with HIV/AIDS.

Authors:  Benjamin J Park; Kathleen A Wannemuehler; Barbara J Marston; Nelesh Govender; Peter G Pappas; Tom M Chiller
Journal:  AIDS       Date:  2009-02-20       Impact factor: 4.177

6.  Outcomes of cryptococcal meningitis in Uganda before and after the availability of highly active antiretroviral therapy.

Authors:  Andrew Kambugu; David B Meya; Joshua Rhein; Meagan O'Brien; Edward N Janoff; Allan R Ronald; Moses R Kamya; Harriet Mayanja-Kizza; Merle A Sande; Paul R Bohjanen; David R Boulware
Journal:  Clin Infect Dis       Date:  2008-06-01       Impact factor: 9.079

7.  Immune reconstitution inflammatory syndrome in HIV-associated cryptococcal meningitis: a prospective study.

Authors:  Tihana Bicanic; Graeme Meintjes; Kevin Rebe; Anthony Williams; Angela Loyse; Robin Wood; Madeleine Hayes; Shabbar Jaffar; Thomas Harrison
Journal:  J Acquir Immune Defic Syndr       Date:  2009-06-01       Impact factor: 3.731

8.  Fungal burden, early fungicidal activity, and outcome in cryptococcal meningitis in antiretroviral-naive or antiretroviral-experienced patients treated with amphotericin B or fluconazole.

Authors:  Tihana Bicanic; Graeme Meintjes; Robin Wood; Madeleine Hayes; Kevin Rebe; Linda-Gail Bekker; Thomas Harrison
Journal:  Clin Infect Dis       Date:  2007-05-25       Impact factor: 9.079

9.  Outcome of AIDS-associated cryptococcal meningitis initially treated with 200 mg/day or 400 mg/day of fluconazole.

Authors:  C F Schaars; G A Meintjes; C Morroni; F A Post; G Maartens
Journal:  BMC Infect Dis       Date:  2006-07-18       Impact factor: 3.090

10.  Dose response effect of high-dose fluconazole for HIV-associated cryptococcal meningitis in southwestern Uganda.

Authors:  Nicky Longley; Conrad Muzoora; Kabanda Taseera; James Mwesigye; Joselyne Rwebembera; Ali Chakera; Emma Wall; Irene Andia; Shabbar Jaffar; Thomas S Harrison
Journal:  Clin Infect Dis       Date:  2008-12-15       Impact factor: 9.079

View more
  9 in total

1.  Global burden of disease of HIV-associated cryptococcal meningitis: an updated analysis.

Authors:  Radha Rajasingham; Rachel M Smith; Benjamin J Park; Joseph N Jarvis; Nelesh P Govender; Tom M Chiller; David W Denning; Angela Loyse; David R Boulware
Journal:  Lancet Infect Dis       Date:  2017-05-05       Impact factor: 25.071

2.  Host response to pulmonary fungal infections: A highlight on cell-driven immunity to Cryptococcus species and Aspergillus fumigatus.

Authors:  Orchi Dutta; Jorge A Masso-Silva; Keyi Wang; Amariliz Rivera
Journal:  Curr Pharmacol Rep       Date:  2017-10-14

3.  Discovery of a Novel Dibromoquinoline Compound Exhibiting Potent Antifungal and Antivirulence Activity That Targets Metal Ion Homeostasis.

Authors:  Haroon Mohammad; Nehal H Elghazawy; Hassan E Eldesouky; Youssef A Hegazy; Waleed Younis; Larisa Avrimova; Tony Hazbun; Reem K Arafa; Mohamed N Seleem
Journal:  ACS Infect Dis       Date:  2018-02-02       Impact factor: 5.084

Review 4.  Integrated therapy for HIV and cryptococcosis.

Authors:  Sirawat Srichatrapimuk; Somnuek Sungkanuparph
Journal:  AIDS Res Ther       Date:  2016-11-29       Impact factor: 2.250

Review 5.  Coinfections and comorbidities in African health systems: At the interface of infectious and noninfectious diseases.

Authors:  Derick Nii Mensah Osakunor; David Moinina Sengeh; Francisca Mutapi
Journal:  PLoS Negl Trop Dis       Date:  2018-09-20

6.  Neurological disorders in a consultant hospital in Northern Tanzania. A cohort study.

Authors:  Saitore Laizer; Kajiru Kilonzo; Sarah Urasa; Venance Maro; Richard Walker; William Howlett
Journal:  eNeurologicalSci       Date:  2018-11-27

Review 7.  Neurological disorders in HIV in Africa: a review.

Authors:  William P Howlett
Journal:  Afr Health Sci       Date:  2019-06       Impact factor: 0.927

8.  Prevalence of Cryptococcal Antigenemia and associated factors among HIV/AIDS patients on second-line antiretroviral therapy at two hospitals in Western Oromia, Ethiopia.

Authors:  Nuguse Geda; Tafese Beyene; Regea Dabsu; Hylemariam Mihiretie Mengist
Journal:  PLoS One       Date:  2019-12-05       Impact factor: 3.240

9.  Mortality from HIV-associated meningitis in sub-Saharan Africa: a systematic review and meta-analysis.

Authors:  Mark W Tenforde; Alida M Gertz; David S Lawrence; Nicola K Wills; Brandon L Guthrie; Carey Farquhar; Joseph N Jarvis
Journal:  J Int AIDS Soc       Date:  2020-01       Impact factor: 5.396

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.